Anika Therapeutics Inc (ANIK)

$16.3

-0.77

(-4.51%)

Market is closed - opens 8 PM, 06 Nov 2024

Performance

  • $16.15
    $17.24
    $16.30
    downward going graph

    0.92%

    Downside

    Day's Volatility :6.32%

    Upside

    5.45%

    downward going graph
  • $16.00
    $29.12
    $16.30
    downward going graph

    1.84%

    Downside

    52 Weeks Volatility :45.05%

    Upside

    44.02%

    downward going graph

Returns

PeriodAnika Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-33.71%
0.0%
0.0%
6 Months
-38.73%
4.2%
0.0%
1 Year
-19.48%
15.2%
0.0%
3 Years
-62.09%
10.5%
-27.4%

Highlights

Market Capitalization
252.6M
Book Value
$12.18
Earnings Per Share (EPS)
-6.86
PEG Ratio
1.25
Wall Street Target Price
26.5
Profit Margin
-59.4%
Operating Margin TTM
-64.29%
Return On Assets TTM
-4.01%
Return On Equity TTM
-43.31%
Revenue TTM
164.2M
Revenue Per Share TTM
11.14
Quarterly Revenue Growth YOY
-6.5%
Gross Profit TTM
96.8M
EBITDA
-8.2M
Diluted Eps TTM
-6.86
Quarterly Earnings Growth YOY
-0.5
EPS Estimate Current Year
-1.45
EPS Estimate Next Year
0.09
EPS Estimate Current Quarter
-0.01
EPS Estimate Next Quarter
0.11

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Anika Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 62.58%

Current $16.30
Target $26.50

Company Financials

FY18Y/Y Change
Revenue
105.6M
↓ 6.93%
Net Income
18.7M
↓ 41.16%
Net Profit Margin
17.74%
↓ 10.31%
FY19Y/Y Change
Revenue
114.6M
↑ 8.58%
Net Income
27.2M
↑ 45.25%
Net Profit Margin
23.73%
↑ 5.99%
FY20Y/Y Change
Revenue
130.5M
↑ 13.83%
Net Income
-24.0M
↓ 188.19%
Net Profit Margin
-18.38%
↓ 42.11%
FY21Y/Y Change
Revenue
147.8M
↑ 13.29%
Net Income
4.1M
↓ 117.24%
Net Profit Margin
2.8%
↑ 21.18%
FY22Y/Y Change
Revenue
156.2M
↑ 5.71%
Net Income
-14.9M
↓ 459.43%
Net Profit Margin
-9.51%
↓ 12.31%
FY23Y/Y Change
Revenue
166.7M
↑ 6.67%
Net Income
-82.7M
↑ 456.34%
Net Profit Margin
-49.6%
↓ 40.09%
Q2 FY23Q/Q Change
Revenue
44.3M
↑ 16.82%
Net Income
-2.7M
↓ 73.52%
Net Profit Margin
-6.19%
↑ 21.1%
Q3 FY23Q/Q Change
Revenue
41.5M
↓ 6.4%
Net Income
-6.6M
↑ 139.91%
Net Profit Margin
-15.86%
↓ 9.67%
Q4 FY23Q/Q Change
Revenue
43.0M
↑ 3.63%
Net Income
-63.0M
↑ 858.03%
Net Profit Margin
-146.61%
↓ 130.75%
Q1 FY24Q/Q Change
Revenue
40.5M
↓ 5.7%
Net Income
-4.5M
↓ 92.83%
Net Profit Margin
-11.14%
↑ 135.47%
Q2 FY24Q/Q Change
Revenue
41.9M
↑ 3.45%
Net Income
-88.0K
↓ 98.05%
Net Profit Margin
-0.21%
↑ 10.93%
Q3 FY24Q/Q Change
Revenue
38.8M
↓ 7.56%
Net Income
-29.9M
↑ 33897.73%
Net Profit Margin
-77.2%
↓ 76.99%
FY18Y/Y Change
Total Assets
279.0M
↓ 1.28%
Total Liabilities
15.4M
↓ 19.58%
FY19Y/Y Change
Total Assets
330.7M
↑ 18.54%
Total Liabilities
42.3M
↑ 175.22%
FY20Y/Y Change
Total Assets
365.6M
↑ 10.55%
Total Liabilities
93.2M
↑ 120.18%
FY21Y/Y Change
Total Assets
347.5M
↓ 4.94%
Total Liabilities
60.5M
↓ 35.14%
FY22Y/Y Change
Total Assets
349.1M
↑ 0.46%
Total Liabilities
63.6M
↑ 5.15%
FY23Y/Y Change
Total Assets
270.6M
↓ 22.48%
Total Liabilities
58.4M
↓ 8.18%
Q2 FY23Q/Q Change
Total Assets
328.9M
↓ 3.01%
Total Liabilities
54.9M
↓ 10.77%
Q3 FY23Q/Q Change
Total Assets
328.2M
↓ 0.22%
Total Liabilities
57.7M
↑ 5.11%
Q4 FY23Q/Q Change
Total Assets
270.6M
↓ 17.53%
Total Liabilities
58.4M
↑ 1.21%
Q1 FY24Q/Q Change
Total Assets
263.7M
↓ 2.55%
Total Liabilities
55.2M
↓ 5.41%
Q2 FY24Q/Q Change
Total Assets
262.7M
↓ 0.41%
Total Liabilities
52.3M
↓ 5.24%
Q3 FY24Q/Q Change
Total Assets
231.4M
↓ 11.9%
Total Liabilities
51.5M
↓ 1.48%
FY18Y/Y Change
Operating Cash Flow
34.9M
↓ 14.44%
Investing Cash Flow
-50.3M
↑ 302.7%
Financing Cash Flow
-28.9M
↓ 9305.1%
FY19Y/Y Change
Operating Cash Flow
37.0M
↑ 5.98%
Investing Cash Flow
39.7M
↓ 178.98%
Financing Cash Flow
-8.1M
↓ 71.83%
FY20Y/Y Change
Operating Cash Flow
13.1M
↓ 64.69%
Investing Cash Flow
-71.3M
↓ 279.55%
Financing Cash Flow
-3.8M
↓ 53.65%
FY21Y/Y Change
Operating Cash Flow
8.4M
↓ 35.73%
Investing Cash Flow
-3.1M
↓ 95.62%
Financing Cash Flow
-6.8M
↑ 79.62%
FY22Y/Y Change
Operating Cash Flow
4.4M
↓ 47.49%
Investing Cash Flow
-7.5M
↑ 140.09%
Financing Cash Flow
-4.9M
↓ 28.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.6M
↓ 852.18%
Investing Cash Flow
-1.4M
↓ 45.08%
Financing Cash Flow
-1.6M
↓ 341.83%
Q2 FY23Q/Q Change
Operating Cash Flow
-8.3M
↑ 129.22%
Investing Cash Flow
-1.5M
↑ 4.9%
Financing Cash Flow
-4.9M
↑ 206.45%

Technicals Summary

Sell

Neutral

Buy

Anika Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Anika Therapeutics Inc
Anika Therapeutics Inc
-29.9%
-38.73%
-19.48%
-62.09%
-72.74%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.46%
-14.95%
5.72%
29.31%
17.74%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-2.69%
18.45%
20.35%
31.71%
31.71%
Zoetis Inc.
Zoetis Inc.
-6.46%
5.56%
7.36%
-19.17%
45.68%
Viatris Inc.
Viatris Inc.
1.06%
-3.13%
24.32%
-16.61%
-29.93%
Catalent, Inc.
Catalent, Inc.
-3.17%
4.12%
71.21%
-51.98%
16.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Anika Therapeutics Inc
Anika Therapeutics Inc
NA
NA
1.25
-1.45
-0.43
-0.04
NA
12.18
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
32.58
32.58
0.28
4.16
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.62
28.62
1.44
0.38
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
35.68
35.68
2.58
5.82
0.49
0.14
0.01
10.9
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.67
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.94
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Anika Therapeutics Inc
Anika Therapeutics Inc
Buy
$252.6M
-72.74%
NA
-59.4%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.4B
17.74%
32.58
17.21%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$44.0B
31.71%
28.62
10.75%
Zoetis Inc.
Zoetis Inc.
Buy
$82.4B
45.68%
35.68
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-29.93%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.7B
16.38%
211.02
-23.81%

Insights on Anika Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 41.92M → 38.75M (in $), with an average decrease of 7.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -88.0K → -29.91M (in $), with an average decrease of 33897.7% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 66.4% return, outperforming this stock by 85.6%

  • Vs NBIX

    In the last 3 years, Anika Therapeutics Inc has experienced a drawdown of -62.1%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 10.1%

Institutional Holdings

  • Trigran Investments Inc

    14.44%
  • BlackRock Inc

    10.86%
  • Caligan Partners LP

    9.70%
  • Morgan Stanley - Brokerage Accounts

    6.79%
  • Vanguard Group Inc

    5.34%
  • Dimensional Fund Advisors, Inc.

    5.06%

Company Information

who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an

Organization
Anika Therapeutics Inc
Employees
357
CEO
Dr. Cheryl Renee Blanchard Ph.D.
Industry
Health Technology

FAQs